In the Randomized Evaluation of Long-Term Anticoagulant Therapy ( RELY ) trial , dabigatran , with 80 % renal elimination , displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150-mg dose and significantly less major bleeding in the 110-mg dose in 18 113 patients with nonvalvular atrial fibrillation .